Monoclonal antibody RFB4-ricin chain A conjugate

Drug Profile

Monoclonal antibody RFB4-ricin chain A conjugate

Alternative Names: Anti-CD22 monoclonal antibody RFB4-ricin chain A conjugate; IgG-RFB4-SMPT-dgA; NSC 639179; RFB4-SMPT-dgA

Latest Information Update: 19 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA)
  • Class Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported B cell lymphoma

Most Recent Events

  • 28 Feb 2003 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
  • 09 Apr 2002 No development reported - Phase-I for Lymphoma in USA (IV-infusion)
  • 10 Jul 2000 A phase I study has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top